New hope for pancreatic cancer: targeted combo trial opens
NCT ID NCT07240766
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (HRS-4642, nimotuzumab, and chemotherapy) in 40 people with a specific type of pancreatic cancer that has a KRAS G12D mutation and is borderline removable. The goal is to see if the treatment can shrink the tumor enough for surgery and prevent it from coming back. Participants must not have had prior cancer therapy and must be between 18 and 75 years old.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Zhejiang University Schlool of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310000, China
-
the First Affiliated Hospital of Zhejiang University, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a common blood pressure pill boost radiation against tough pancreatic tumors?
- New hope for pancreatic cancer: drug combo aims to shrink tumors before surgery
- Triple punch against pancreatic cancer: chemo, immunotherapy, and radiation before surgery
- New chemo sequence aims to make pancreatic tumors operable
- New drug cocktail aims to tackle tough pancreatic cancer